Use of specific genes for the prognosis of lung cancer and the corresponding prognosis method

Abstract

At least 13 genes chosen among a set of 28 genes for carrying out a method for identifying at least 66% of patients of those having a survival rate of at most about 20% at 30 months, among a population of patients afflicted by lung cancer having an estimated survival rate of at least 30% at 30 months based on the diagnosis of the lung cancer according to histopathological criteria.

1 . An element consisting of:
 at least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,   or fragments of said least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,   or complementary sequences of said least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,   or sequences having at least 80% homology with said genes or fragment thereof,   or proteins coded by said least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences   or fragments of said proteins,   or antibodies directed against said proteins,   said at least 13 genes being such that   12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and   at least one gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97,   
       said element suitable for carrying out a method for identifying at least 66% of patients of those having a survival rate of at most about 20% at 30 months, among a population of patients afflicted by lung cancer having an estimated survival rate of at least 30% at 30 months based on the diagnosis of said lung cancer according to histopathological criteria. 
     
     
         2 . The element according to  claim 1 , of
 at least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,   or fragments of said least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,   or complementary sequences of said least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,   or sequences having at least 80% homology with said genes or fragments thereof,   said at least 13 genes being such that   12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and   at least one gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97,   
       for carrying out a method for identifying at least 66% of patients of those having a survival rate of at most about 20% at 30 months, among a population of patients afflicted by lung cancer having an estimated survival rate of at least 30% at 30 months based on the diagnosis of said lung cancer according to histopathological criteria. 
     
     
         3 . The element according to  claim 2 , wherein said at least one gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, is at least the gene comprising or consisting of the nucleic acid sequences SEQ ID NO: 82,
 for carrying out a method for identifying at least 70% of patients having a survival rate of at most about 20% at 30 months.   
     
     
         4 . The element according to  claim 2 , of at least 18 genes
 said at least 18 genes being such that
 a. 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
 b. at least 6 genes belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least 6 genes comprising or consisting of the nucleic acid sequences SEQ ID NO:82-85 and 87-88, 
   
       for carrying out a method for identifying at least 83% of patients of those having a survival rate of at most about 20% at 30 months. 
     
     
         5 . The element according to  claim 2 , of at least 21 genes,
 said at least 21 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
 at least 9 gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least 9 genes preferably comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-88 and 91-92, 
   
       for carrying out a method for identifying at least 89% of patients having a survival rate of at most about 20% at 30 months. 
     
     
         6 . The element according to  claim 2 , of at least 26 genes
 said at least 26 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
 at least 14 gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least 14 genes preferably comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-92 and 93-96, 
   
       for carrying out a method for identifying at least 97% of patients of those having a survival rate of at most about 20% at 30 months. 
     
     
         7 . The element according to  claim 2 , of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 70-97 for carrying out a method for identifying 100% of patients of those having a survival rate of at most about 20% at 30 months. 
     
     
         8 . Method, preferably in vitro, for identifying patient afflicted by a lung cancer having of the survival rate of at most about 20% at 30 months, among a population of patients afflicted by lung cancer having an estimated survival rate of at least 30% at 30 months based on the diagnosis of said lung cancer according to histopathological criteria,
 said method allowing the identification of at least 66% of patient of those afflicted by a lung cancer having of the survival rate of at most about 20% at 30 months,   said method comprising
 a step of measuring, in a biological sample of said patients, the expression of
 at least 13 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97, 
 or fragments of said genes 
 or complementary sequences of said genes 
 
 said at least 13 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
 at least one gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, and 
 
 a step of identifying biological samples expressing said at least 13 genes. 
   
     
     
         9 . Method, according to  claim 8 , wherein said at least 13 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and   at least one gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least one gene comprising or consisting of the nucleic acid sequences SEQ ID NO: 82,   
       said method allowing the identification of at least 70% of patients of those afflicted by a lung cancer having of the survival rate of at most about 20% at 30 months. 
     
     
         10 . Method, according to  claim 8 , said method comprising a step of measuring, in a biological sample of said patients, the expression of at least 18 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,
 said at least 18 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
   at least 6 genes belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least 6 genes comprising or consisting of the nucleic acid sequences SEQ ID NO:82-85 and 87-88,   said method allowing the identification of at least 83% of patients of those having a survival rate of at most about 20% at 30 months.   
     
     
         11 . Method, according to  claim 8 , said method comprising a step of measuring, in a biological sample of said patients, the expression of at least 21 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,
 said at least 21 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
 at least 9 gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least 9 genes preferably comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-88 and 91-92, 
   said method allowing identifying at least 91% of patients having a survival rate of at most about 20% at 30 months.   
     
     
         12 . Method, according to  claim 8 , said method comprising a step of measuring, in a biological sample of said patients, the expression of at least 26 genes chosen among a set of 28 genes comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,
 said at least 26 genes being such that
 12 genes comprise or consist of the nucleic acid sequences SEQ ID NO: 70 to 81, and 
 at least 14 gene belongs to a subset of 16 genes comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-97, said at least 14 genes preferably comprising or consisting of the nucleic acid sequences SEQ ID NO: 82-92 and 93-96, 
   said method allowing identifying 100% of patients of those having a survival rate of at most about 20% at 30 months.   
     
     
         13 . Method, according to  claim 8 , said method comprising a step of measuring, in a biological sample of said patients, the expression of 28 genes chosen comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97,
 said method allowing identifying 100% of patients of those having a survival rate of at most about 20% at 30 months.   said method allowing the identification of 100% of patient afflicted by a lung cancer having of the survival rate of at most about 20% at 30 months
 said method comprising
 a step of measuring, in a biological sample of said patients, the expression of 28 comprising or consisting of the nucleic acid sequences SEQ ID NO 70 to 97, and 
 
 a step of identifying biological samples expressing said 28 genes.